Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after <scp>HB</scp> eAg seroconversion is associated with high relapse rates and fatal outcomes

Abstract

Treatment withdrawal in Caucasian chronic hepatitis B patients after nucleos(t)ide analogue-induced HBeAg seroconversion results in viral relapses in more than half of patients with potential fatal outcomes. These real-world data further lend support to preferentially continue NA treatment after HBeAg seroconversion until HBsAg loss.